Heidi Fiegl
High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome
Wolf D, Reimer D, Hartmann G, Sopper S, Sprung S, Marth C, Wieser V, Zeimet A, Fiegl H, Bösch M. High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome. Int J Cancer 2019
04.12.2019High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome
04.12.2019Int J Cancer 2019
Wolf Dominik, Reimer Daniel, Hartmann Gunther, Sopper Sieghart, Sprung Susanne, Marth Christian, Wieser Verena, Zeimet Alain G, Fiegl Heidi, Bösch Maximilian
Evaluation of Vav3.1 as prognostic marker in endometrial cancer
Bösch M, Reimer D, Wolf D, Hatina J, Rössler J, Wiedemair A, Fiegl H, Marth C, Sopper S, Zeimet A. Evaluation of Vav3.1 as prognostic marker in endometrial cancer. J Cancer Res Clin Oncol 2018; 144:2067-2076.
06.08.2018Evaluation of Vav3.1 as prognostic marker in endometrial cancer
06.08.2018J Cancer Res Clin Oncol 2018; 144:2067-2076
Bösch Maximilian, Reimer Daniel, Wolf Dominik, Hatina Jiri, Rössler Julia, Wiedemair Annemarie, Fiegl Heidi, Marth Christian, Sopper Sieghart, Zeimet Alain G
High prevalence of side population in human cancer cell lines
Bösch M, Zeimet A, Fiegl H, Wolf B, Huber J, Klocker H, Gastl G, Sopper S, Wolf D. High prevalence of side population in human cancer cell lines. Oncoscience 2016; 3:85-87.
10.04.2016High prevalence of side population in human cancer cell lines
10.04.2016Oncoscience 2016; 3:85-87
Bösch Maximilian, Zeimet Alain G, Fiegl Heidi, Wolf Barbara, Huber Julia, Klocker Helmut, Gastl Guenther, Sopper Sieghart, Wolf Dominik